Comparison of In-Cell Immunoassay and Automated Electrophysiology for Assessment of Herg Trafficking Liability for New Drugs
Comparison of in-cell immunoassay and automated electrophysiology for assessment of hERG trafficking liability for new drugs
Yuri Kuryshev, Peter Hawryluk, Caiyun Wu, Abby Sewell, James Kramer, Carlos Obejero-Paz, Luke Armstrong, Arthur M. Brown Charles River, Cleveland, Ohio, USA
IWB/PPC 1 h IWB/PPC 24 h 1.8 1.8 hERG-Lite 16 h hERG-Lite 1 h 1 3 1.6 Abstract Results 1.6 4 Summary 1.4 1.4 hERG-Lite® is an antibody-based chemiluminescent assay that identifies compounds that disrupt Voltage clamp population patch: functional assay for 1.2 1.2 trafficking or suppress expression of hERG channel protein. Electrophysiological recording from measuring relative changes in membrane surface hERG 1.0 1.0 hERG-Lite® : in-cell immunoassay for measuring relative single cell using the manual patch-clamp technique is more direct way to quantify hERG expression in 0.8 0.8 0.6 0.6 cell membrane but this method has critical limitations: low throughput and selection bias during choice channelAa levels Ab Vehicle Control Pentamidine changes in hERG channel surface levels 24 hr. 1 hr. 0.4 0.4 Fraction of Control Fraction of Control of cells for patching. Application of the automated population patch clamp technique for the hERG 1hr. 30 M/1 hr. 30 M 30 M 0.2 0.2 VC Pent. VC Pent. expression analysis provides a dramatic increase in throughput and eliminates the cell selection bias. 0.0 0.0 hERG-Lite WB* IWB/PPC We analyzed a panel of drugs (Amiodarone, Amitriptyline, Bepridil, Diphenhydramine, Dofetilide, 0.03 0.1 0.3 1 0.03 0.1 0.3 1 Amiodarone ↓ ↓ N.D.** Fluoxetine, Imipramine, Ouabaine, Pentamidine, Pimozide, Sunitinib and Verapamil) for chronic effects Pimozide, M Pimozide, M Amitriptyline ↓ ↓ ↓ on hERG channel trafficking and expression by the hERG-Lite® method and with IonWorks Barracuda IWB/PPC 1 h IWB/PPC 24 h hERG-Lite 1 h hERG-Lite 16 h (IWB), a population-based automated patch clamp platform. We find that the hERG-Lite® assay is the 1.2 1.2 Diphenhydramine N.E. - N.E. 24 hr. more accurate method to detect direct drug effects on hERG trafficking with lower probability of false Dofetilide N.E. N.E. N.D.** positive and false negative hits. In the population patch clamp-based assay, all of the hERG-Lite- 1.0 1.0 30 M/24 hr. Fluoxetine N.E.*** ↓ ↓ positive drugs also reduced hERG currents after chronic (overnight) treatment followed by washout. 0.8 0.8 However, certain hERG-Lite-negative drugs, followed by washout, reduced hERG activity detected by Imipramine ↓ - ↓ 0.6 0.6 IWB. Such drugs also displayed classic hERG block after acute application to cells on IWB, and Pentamidine ↓ ↓ ↓ reduced hERG currents after incubation times (1 h) too short to affect trafficking. We conclude that 0.4 0.4 Pimozide N.E. N.E. N.D.** Pentamidine Fraction of Control population electrophysiological assays, and likely manual patch clamp assays, are prone to false- 110 Fraction of Control 0.2 0.2 100 24 hr. Sunitinib N.E. N.E. N.D.** 90 24 hr. positives with lipophilic hERG-blocking compounds, which appear to be retained in cell membranes at 80 70 M 0.0 Verapamil N.E. N.E. N.E. 0.0 sufficient concentrations after washout to directly block hERG channel activity. 50 60
Inhibition 1 hr. 30 1 3 10 30 1 3 10 30
% 40 1 hr. Amiodarone, M Amiodarone, M For all compound results are obtained from 3-4 independent experiments (each assay). Positive or 10 30 with
% Inhibition Pentamidine Pentamidine 20 -10 Negative results were consistent or all 3-4 experiments 10 100 0 Conc (uM) Figure 3. Measured effects of hERG inhibition with Pimozide and Amiodarone N.D., Trafficking effects were not detected; N.E., No effect *Wester Blot data from the present study or published Western Blot and long-treatment data Mean ± SD; N=15-16; IC50. (24hr) = 14.9 IWB/PPC (gray) vs. hERG-Lite (black); 24 hours (left) vs. 1 hour (right). Averaged data from 3 IWB and 4 hERG-Lite M experiments; Mean + SD. **Significant dose-dependent inhibition was detected after 1 hour and 24 hour treatments Figure 1. hERG currents on IWB platform; PPC mode. Effect of Pentamidine – 1 hour vs. and 24 hours treatment ***Non-significant trafficking inhibition effects were obtained in hERG-Lite experiments where solutions 2 Methods A, representative hERG current traces. B, Dose-response of Pentamidine produced inhibition of hERG expression. C, contained FBS but inhibition was seen in absence of FBS in the media IonWorks™ Barracuda based assay reproducibility of Pentamidine effect on hERG expression; each point represent mean of N = 14-16 wells from independent experiments. Cells and Treatment. HEK293 cells were transfected with KCNH2 encoding cDNA. Stable transfectants were Assay Limitation IWB/PPC hERG-Lite selected using the G418-resistance gene incorporated into the expression plasmid. Cells were cultured in IWB/PPC 1 h IWB/PPC 24 h Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (D-MEM/F-12) supplemented with 10% fetal bovine serum, 1.2 hERG-Lite 1h 1.2 hERG-Lite 16 h Western Blot: Biochemical assay for measuring relative Trafficking effects not detected due to compound Yes No
100 U/mL penicillin G sodium, 100 g/mL streptomycin sulfate and 500 g/mL G418. Test article concentrations were 1.0 1.0 retention diluted in the cell culture media and applied to the cells in 60-mm dishes for 1 or 24 hours; final concentration DMSO changes of compartmentalized intracellular and surface hERG was 0.3%. Vehicle control cells were incubated with 0.3% DMSO for 1 or 24 hours. To verify the sensitivity of the 0.8 0.8 assay, one concentration of the positive control (pentamidine: 30 M; 0.3% DMSO) was applied to the cells for 1 or channel forms 0.6 24 hours. Before testing, cells in culture dishes were washed three times with Hank’s Balanced Salt Solution (HB- 0.6 Amiodarone Pimozide PS) to remove the culture medium and test articles then treated with Accutase™ for up to 60 minutes. Immediately 0.4 0.4 before use in IonWorks system, the cells were washed twice in HB-PS to remove the Accutase and re-suspended in
Conclusions
0.2 0.2 5 the final volume of HB-PS. Fraction of Control Fraction of Control
Pent Pent
Pent Pent M
M
M M
0.0 μ
M M μ
0.0
M M
M M M μ M M μ M μ μ M M M M M M μ μ
Electrophysiological Procedures. In preparation for a recording session, the intracellular solution (in mM: 70 KCl, μ μ μ 3 10 30 100 3 10 30 100 μ HEK UT HEK 3 HEK UT HEK 0.1 1 3 30 μ 0.3 Vehicle 0.03 30 10 μ 30 μ 1 0.1 30 Vehicle 1 0.3 0.03 30 10 μ 1 30 Vehicle Vehicle • hERG-Lite® is the only medium throughput, cost effective assay to 70 KF, 2 MgCl2, 1 EGTA, 10 HEPES) was loaded into the intracellular compartment of the population patch clamp Pentamidine, M Pentamidine, M (PPC™) planar electrode. Extracellular buffer (HEPES-buffered Physiological Saline; HB-PS) was loaded into the 150 150 identify drugs that decrease hERG trafficking. PPC plate wells (11 l per well). Cell suspensions (vehicle control, positive control and test compound treated cells) IWB/PPC 1 h IWB/PPC 24 h 1.2 1.2 The IWB/PPP method identifies hERG trafficking inhibition and drug hERG-Lite 1 h hERG-Lite 16 h • were pipetted into the wells of the PPC planar electrode (9 l per well). After establishment of a whole-cell 1h Treatment 24h** Treatment 1h Treatment 24h Treatment configuration (the perforated patch: Escin), membrane currents were recorded using patch clamp amplifier in the 1.0 1.0 accumulation.
IonWorks™ Barracuda system (IWB). Each IWB experiment had included: two (2) treatments – 1 and 24 hours with two (2) test articles per treatment (4 concentrations, N = 16 per concentration), the positive control (one 0.8 0.8 Figure 4. Amiodarone inhibits hERG trafficking – Western Blot Analysis concentrations, N = 32) and the vehicle control (N = 32). Western blot showing effect of 1- and 24-hour treatment of HEK 293 [H71] cells stably expressing hERG with 0.6 0.6 increasing concentrations of Pimozide and Amiodarone. Amiodarone-treated cells exhibited an increase in core- hERG current was elicited using a pulse pattern with fixed amplitudes (conditioning pre-pulse: 20 mV for 2000 ms; glycosylated hERG (135 KDa) with increasing treatment time and drug concentration. Pimozide – treated cells test pulse: -40 mV for 500 ms) from a holding potential of -80 mV. hERG current amplitude was measured as a 0.4 0.4 exhibited fully glycosylated hERG (150 KDa) under all conditions, indicating that Pimozide has no effect on peak current at the test step to -40 mV. hERG trafficking to the cell surface. 0.2 0.2 Western Blot Protocol: Cells were rinsed in ice cold DPBS, followed by direct lysis in TmPER (FIVEPhoton) Fraction of Control Fraction of Control for 5 minutes on ice. Protein concentrations were assayed by Coomassie Plus Bradford Assay Kit. SDS-PAGE 0.0 0.0 hERG-Lite® was run with 10 μg whole cell lysate per lane on a 4-12% Bis-Tris gel. Proteins were transferred to PVDF hERG-Lite® experiments were performed as described previously: Wible BA, Hawryluk P, Ficker E, Kuryshev YA, 1 3 10 30 1 3 10 30 Imipramine, M Imipramine, M overnight at a 12 V constant. Antibodies: Polyclonal Rabbit anti-hERG (Alomone, APC-109), followed by Kirsch G, Brown AM. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J incubation with Goat anti-Rabbit HRP-conjugated secondary antibody (Santa Cruz). Blots were developed in Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):136-45. Figure 2. Measured effects of hERG inhibition with Pentamidine and Imipramine SuperSignal West Pico ECL reagent and signal was detected with X-ray film.
IWB/PPC (gray) vs. hERG-Lite (black); 24 hours (left) vs. 1 hour (right). Averaged data from 3 IWB and 4 hERG-Lite experiments; Mean + SD.